Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.

NCT Number	NCT06841172
Lead Sponsor	Shandong Cancer Hospital and Institute
Conditions	OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Enrollment	132 participants
Start Date	2025-07-21
Primary Completion	2027-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-01